 SAN JOSE, Calif., April 16, 2021 GLOBE NEWSWIRE -- AnPac Bio-Medical Science Co., Ltd. AnPac Bio, the Company or we NASDAQ: ANPC, a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its paid tests based on the cancer differentiation analysis technology CDA technology, or paid CDA-based tests, in the first quarter of 2021, setting a record high Q1 test volume. CDA-based tests, which are multi-cancer tests based on a novel biophysical approach, are the Companys flagship product line and reached 5,439 paid cancer tests in Q1, an approximately 130 increase over the same period last year. While AnPac Bio offers multiple test products including various cancer screening tests, immunology tests and annual physical checkups, paid CDA-based tests had the highest test volume among all these tests in Q1, 2021. 